Highmark and AstraZeneca Enter Outcomes-Based Agreement For Fasenra Asthma Medication

Highmark, Inc., entered an outcomes-based agreement with AstraZeneca for Fasenra, an add-on injected prescription maintenance treatment for people age 12 and older with severe asthma. The agreement applies to Highmark’s commercial and Medicare members; about 500 Highmark members currently use Fasenra. For this agreement, Highmark is measuring medication adherence, and improvements in member health.

Highmark has previously entered into value-based contracts for pharmaceutical and biological treatments for several other chronic, high-cost health conditions, including diabetes, autoimmune diseases, asthma, and chronic obstructive pulmonary (COPD). It had previously entered an outcomes-based agreement with AstraZeneca for Symbicort . . .